Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Patent metadata

Field	Value
Publication number	US-10137118-B2
Application number	US-201715801152-A
Country	US
Kind code	B2
Filing date	Nov 1, 2017
Priority date	Feb 7, 2014
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

First claim

The invention claimed is:

1. A crystalline ansolvate of Compound 1:

characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48 °2θ (each ±0.2 °2θ).

2. The crystalline ansolvate of claim 1 , characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to FIG. 7 .

3. The crystalline ansolvate of claim 1 , characterized by an endothermic peak at 95° C.±2° C. as measured by differential scanning calorimetry.

4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline ansolvate of Compound 1:

characterized by at least three X-ray powder diffraction peaks (Cu Kα radiation) selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48 °2θ (each ±0.2 °2θ). selected from 11.65°, 11.85°, 12.08°, 16.70°, 19.65° and 23.48 °2θ (each ±0.2 °2θ).

5. The pharmaceutical composition of claim 4 , wherein the crystalline ansolvate of Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to FIG. 7 .

6. The pharmaceutical composition of claim 4 , wherein the crystalline ansolvate of Compound 1 is characterized by an endothermic peak at 95° C.±2° C. as measured by differential scanning calorimetry.

Assignees

• Global Blood Therapeutics Inc

Inventors

• Li Zhe
• Parent Stephan D
• Houston Travis

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K31/4439 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title